Canadian Hemodialysis Morbidity Study

American Journal of Kidney Diseases

Volumn 19, Issue 3, 1992, Pages 214-234

  Churchill, David N ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Taylor, D Wayne ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Cook, Richard J ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   LaPlante, Patricia ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Barre, Paul ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Cartier, Pierre ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Fay, William P ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Goldstein, Marc B ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Jindal, Kailash ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Mandin, Henry ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   McKenzie, John K ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Muirhead, Norman ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Parfrey, Patrick S ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Posen, Gerald A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Slaughter, David ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Ulan, Raymond A ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}   Werb, Ronald ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n}  

^a ST JOSEPH S HOSPITAL   (Canada)

^b Ortho Pharmaceuticals ^*  (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^e Laurentian Universtiy   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g Victoria Hospital   (Canada)

^h HEALTH SCIENCES CENTRE   (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^k UNIVERSITY OF OTTAWA   (Canada)

^l University Hospital   (Canada)

^m ST PAUL S HOSPITAL   (Canada)

ⁿ FOOTHILLS HOSPITAL   (Canada)

more..

Author keywords

epidemiology; Hemodialysis; morbidity; mortality; nutrition

Indexed keywords

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANADA; CHRONIC KIDNEY FAILURE; FEMALE; HEMODIALYSIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NUTRITION; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL; THROMBOSIS;

EID: 0026559390     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(13)80002-9     Document Type: Article

References (70)

1. Death risk in hemodialysis patients; the predictive value of commonly measured variables and an evaluation of death rate differences between facilities
2. Changing risk factor demographics in end-stage renal disease patients entering hemodialysis and the impact on long term mortality
3. Predicting survival in adults with end-stage renal disease; an age equivalence index
4. Statistics-Servant of all sciences
5. Non-parametric estimation from incomplete observations
6. Regression models and life tables
7. Mortality risk factors in patients treated by chronic hemodialysis
8. Morbidity and mortality of long term hemodialysis; a review
9. Combined report on regular dialysis and transplantation in Europe
10. Patients surviving 10 years of hemodialysis
11. Survival with dialysis and transplantation in patients with end stage renal disease
12. Smoking, hypertension and mortality in a maintenance dialysis population
13. Survival in patients with end-stage renal disease
14. Income and survival in chronic hemodialysis patients
15. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients
16. A hypothesis; the protein catabolic rate is dependent on the type and amount of treatment in dialyzed patients
17. Cannulation of blood vessels for prolonged hemodialysis
18. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula
19. Expanded polytetrafluoroethylene (PTFE) subcutaneous arteriovenous conduit; an improved vascular access for chronic hemodialysis
20. Arteriovenous graft life in chronic hemodialysis
21. Complications from permanent hemodialysis vascular access
22. Access to the circulation for regular hemodialysis
23. Arteriovenous fistulas for hemodialysis in 100 consecutive patients
24. PTFE grafts for hemodialysis access; techniques for insertion and management of complications
25. Comparison of autogenous fistula versus expanded polyethylene graft fistula for angioaccess in hemodialysis
26. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients
27. Vascular access in a university transplant and dialysis program
28. Management of sepsis involving expanded polytetrafluorethylene grafts for hemodialysis access
29. Medium-term follow-up of forty autogenous vein grafts and forty polytetrafluoroethylene (Gore-Tex) grafts for vascular access
30. Polytetrafluoroethylene graft survival in hemodialysis
31. Complications of vascular access for hemodialysis
32. Asymptomatically efficient rank invariant ,procedures
33. Saphenous vein arteriovenous fistulae in regular dialysis treatment
34. Human umbilical vein graft angio access in chronic hemodialysis-A preliminary report
35. Experience with dacron graft arteriovenous fistulas for dialysis access
36. Alternatives for vascular access; experience with autogenous saphenous vein autografts and bovine heterografts
37. Outcome of vascular accesses for hemodialyses in the elderly (<75 years)
38. Prevention of hemodialysis fistula thrombosis; early detection of venous stenoses
39. Duplex ultrasound scanning in the assessment of arteriovenous fistulas created for vascular access; comparison with digital subtraction angiography
40. Arteriovenous shunt thrombosis
41. Prevention of thrombosis in patients on hemodialysis by low dose aspirin
42. Shunt thrombosis prevention in hemodialysis patients-A double blind, randomized study; pentoxifylline vs placebo
43. Very low doses of warfarin can prevent thrombosis in central venous catheters
44. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis
45. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin
46. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis
47. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
48. Seizures and hypertension events
49. Clinical and serological analysis of transfusion on associated hepatitis
50. Transfusion associated non-A, non-B hepatitis; an assessment of the causative agent and its clinical impact
51. Serum glutamic-pyruvic transaminase in hepatic disease
52. The clinical significance of transaminase activities of serum
53. Bacterial infections in chronic hemodialysis patients; epidemiologic and pathophysiologic aspects
54. Incidence and type of infections occurring in 445 chronic hemodialysis patients
55. Mycobacteriosis in bacteriosis in patients with chronic renal failure
56. Listeriosis in patients with long term hemodialysis and transfusional iron overload
57. Host defences and immunologic alterations associated with chronic hemodialysis
58. Immune deficiency of the uremic patient
59. Protein calorie malnutrition and cutaneous energy in hemodialysis maintained patients
60. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis
61. Impaired phagocytic activity of neutrophils in patients receiving hemodialysis; the critical role of iron overload
62. Predicting nutrition associated complications for patients undergoing gastrointestinal surgery
63. IGF-I, a marker of undernutrition in hemodialysis patients
64. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis
65. Nutritional status and lymphocyte function in maintenance hemodialysis patients
66. Host immune status in uremia (IV); phagocytosis and inflammatory response in vivo
67. C5a receptor modulation on neutrophils and monocytes from chronic hemodialysis and peritoneal dialysis patients
68. Yersinia sepsis in patients with iron overload treated by desferoxamine